|
WO2015082600A1
|
|
Process for preparing influenza vaccines
|
|
WO2015040234A1
|
|
Adenovirus formulations
|
|
ZA201405947B
|
|
Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
|
|
WO2015000832A1
|
|
Method for preparing virosomes
|
|
WO2015000831A1
|
|
Method for preparing virosomes
|
|
SG11201510216RA
|
|
Stabilized soluble pre-fusion rsv f polypeptides
|
|
KR20150124973A
|
|
Acellular pertussis vaccine
|
|
ZA201309304B
|
|
Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
|
|
US2015232537A1
|
|
Human binding molecules capable of binding to and neutralizing hepatitis B viruses and uses thereof
|
|
HK1180008A1
|
|
Method for the production of ad26 adenoviral vectors ad26
|
|
WO2013174910A1
|
|
Adenoviral vectors for transduction of vascular tissue
|
|
US2014186391A1
|
|
Vaccine against RSV
|
|
AP201407994A0
|
|
Vaccine against rsv
|
|
MX2014010873A
|
|
Batches of recombinant adenovirus with altered terminal ends.
|
|
US2014073032A1
|
|
Batches of recombinant adenovirus with altered terminal ends
|
|
CN104169298A
|
|
Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
|
|
US2013236494A1
|
|
Vaccination against influenza
|
|
WO2013131898A1
|
|
Improved vaccination against influenza
|
|
CN104066446A
|
|
Influenza virus vaccines and uses thereof
|
|
US2013122038A1
|
|
Heterologous prime-boost immunization using measles virus-based vaccines
|
